CapsoVision, Inc. (CV) AI Stock Analysis

• Market Cap: $226.39M
• Dividend Yield: N/A
• Average Volume (3M): 45.47K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.23
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 90
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Equipment & Services
• EPS (TTM): N/A
• Shares Outstanding: 46,774,067
• 10 Day Avg. Volume: 21,973
• 30 Day Avg. Volume: 45,470
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.00
• Price Target Upside: 25.52% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 52 Neutral
• Price Target: $4.50 ▼(-5.86% Downside)

CapsoVision, Inc. has a low overall stock score primarily due to its poor financial performance, which is a significant concern. The technical analysis provides some positive momentum, but the lack of valuation data limits a comprehensive assessment. The absence of earnings call and corporate events data further constrains the evaluation.

CapsoVision, Inc. Business Overview & Revenue Model

Company Description

CapsoVision, Inc. (CV) is a pioneering company in the medical technology sector, specializing in the development of innovative gastrointestinal imaging solutions. The company focuses on enhancing patient care through its flagship product, the CapsoCam, a capsule endoscopy system designed to provide high-quality images of the gastrointestinal tract with minimal discomfort for patients. CapsoVision aims to improve diagnostic capabilities and patient outcomes by leveraging advanced imaging technologies and a commitment to continuous innovation in the field of gastrointestinal health.

How the Company Makes Money

CapsoVision generates revenue primarily through the sale of its CapsoCam capsule endoscopy systems and related disposable products, such as the capsules used in procedures. The company also earns revenue from partnerships with healthcare providers and institutions, which may include training, support services, and bulk purchase agreements. Additionally, CapsoVision may explore collaborations with pharmaceutical companies for research and clinical trials, further diversifying its revenue streams. The company's business model is built on establishing a strong presence in hospitals and outpatient clinics, aiming to create long-term relationships that lead to repeat purchases and ongoing service contracts.

CapsoVision, Inc. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	Dec 2024	Dec 2023
Income Statement
Total Revenue	11.76M	9.75M
Gross Profit	6.38M	5.49M
EBITDA	-19.40M	-10.96M
Net Income	-19.90M	-11.30M
Balance Sheet
Total Assets	16.80M	21.53M
Cash, Cash Equivalents and Short-Term Investments	9.32M	14.56M
Total Debt	1.24M	1.51M
Total Liabilities	146.31M	131.37M
Stockholders Equity	-129.51M	-109.84M
Cash Flow
Free Cash Flow	-20.24M	-11.56M
Operating Cash Flow	-20.09M	-10.80M
Investing Cash Flow	-153.00K	-754.00K
Financing Cash Flow	15.07M	20.53M

CapsoVision, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
A	―	$41.02B	33.93	19.88%	0.68%	4.48%	-11.52%
NVST	―	$3.35B	243.42	0.50%	―	4.73%	―
ANGO	―	$487.39M	-15.11	-17.10%	―	2.73%	87.03%
CV	―	$226.39M	―	―	―	―	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NEUE	―	―	―	―	―	-13.83%	87.09%

CapsoVision, Inc. Corporate Events

CapsoVision Announces Leadership Transition Plans

On September 22, 2025, CapsoVision, Inc. announced the planned retirement of Rebecca Petersen, its Senior Director of Clinical Affairs, effective October 15, 2025. Keri Jorgenson has been promoted to Director of Clinical Operations and will lead the clinical development operations, ensuring a seamless transition. Petersen will continue to support the company through a consulting agreement starting October 16, 2025, to facilitate a smooth transition without disrupting operations.

The most recent analyst rating on (CV) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on CapsoVision, Inc. stock, see the CV Stock Forecast page.

CapsoVision CFO Kevin Lundquist Steps Down

On August 27, 2025, Kevin Lundquist stepped down as Chief Financial Officer of CapsoVision, Inc. The company has initiated a search for his successor and agreed on a separation package with Lundquist, which includes severance benefits, a prorated bonus, stock option vesting, and continued healthcare coverage. Lundquist will also provide consulting support to the company for up to six months as part of a Consulting Agreement.

The most recent analyst rating on (CV) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on CapsoVision, Inc. stock, see the CV Stock Forecast page.

CapsoVision Reports Revenue Growth and IPO Success

CapsoVision, Inc. is a commercial-stage medical technology company specializing in advanced imaging and AI-enabled capsule endoscopy solutions, primarily in the gastrointestinal diagnostics sector, with a focus on non-invasive procedures and panoramic imaging technology.